CooperCompanies shares fell 6.22% to close at $63.48 before dropping 15.96% to $53.35 in after-hours trading; they were also reported down more than 15% in Thursday’s premarket session after fiscal third-quarter results and the completion of the company’s strategic review. Revenue rose 1% year over year to $1.066 billion, below Wall Street’s $1.10 billion estimate, while non-GAAP diluted EPS increased 4% to $1.15, above the $1.12 consensus. CooperVision revenue was flat as the company reduced U.S. distribution-channel inventory, and management said the pressure would continue into the fourth quarter. The Board unanimously decided to retain CooperSurgical rather than pursue a sale, reduced full-year fiscal 2026 revenue and non-GAAP diluted EPS guidance, and increased the share-repurchase authorization to $3 billion.